We are thrilled to announce that Impavid has been awarded 2nd place at the prestigious Grand Prix Innovation 2025. Held at the historic Palazzo Mezzanotte in Milan, the event was organized by the CCI France Italie (Chamber of Commerce) and brought together over 500 leaders from the Franco-Italian innovation ecosystem, including startups, research centers, and investors.
Supported by Forvis Mazars, Impavid stood out for its development of the first fully biodegradable bioartificial cardiac patch. Applied directly to the heart, this patch limits pathological remodeling and promotes tissue regeneration after a myocardial infarction, with the potential of improving the quality of life for patients.
From Lab Collaboration to Global Recognition
The transition from a laboratory project to a high-potential startup was made possible by this sustained collaboration:
- The Patent: The core technology was protected through a joint patent between the University of Turin and the National Research Council (CNR-IPCF, Pisa), solidifying the intellectual foundation of what would become Impavid.
- The Launch of Impavid: In 2024, this scientific partnership officially culminated in the founding of Impavid s.r.l., an academic spin-off dedicated to bringing this “heart-repairing patch” to the global medical market.
Today, our team remains deeply connected to its roots, leveraging the ongoing research excellence of our founding institutions to redefine the future of cardiac recovery.
They Are Talking About Us
Our recent success has caught the attention of the scientific and innovation community.
Check out the latest coverage and social media highlights below:
- Università di Torino (OTTO): A patch to repair the heart: Impavid conquers the European innovation landscape
- LinkedIn/Social Media: on the pages of Fovis Mazars Italia; La French Tech Italy; CCI – France Camera di Commercio; G-Factor, incubatore-acceleratore di Fondazione Golinelli